CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES

被引：0

作者：

de Botton, S. ^{[1
]}

Pollyea, D. A. ^{[2
]}

Stein, E. M. ^{[3
]}

DiNardo, C. ^{[4
]}

Fathi, A. T. ^{[5
]}

Roboz, G. J. ^{[6
]}

Collins, R. ^{[7
]}

Swords, R. T. ^{[8
]}

Flinn, I. ^{[9
]}

Altman, J. K. ^{[10
]}

Tallman, M. S. ^{[3
]}

Kantarjian, H. ^{[4
]}

Colby, K. ^{[11
]}

Fan, B. ^{[11
]}

Goldwasser, M. ^{[11
]}

Prahl, M. ^{[11
]}

Agresta, S. ^{[11
]}

Stone, R. M. ^{[12
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Univ Colorado, Ctr Canc, Aurora, CO USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[8] Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Sarah Cannon Res Inst, Nashville, TN USA

[10] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[11] Agios Pharmaceut, Cambridge, MA 02139 USA

[12] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P563

引用

页码：214 / 215

页数：2

共 50 条

[21] Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
DiNardo, Courtney D.
Stein, Eytan M.
de Botton, Stephane
Roboz, Gail J.
Altman, Jessica K.
Mims, Alice S.
Swords, Ronan
Collins, Robert H.
Mannis, Gabriel N.
Pollyea, Daniel A.
Donnellan, Will
Fathi, Amir T.
Pigneux, Arnaud
Erba, Harry P.
Prince, Gabrielle T.
Stein, Anthony S.
Uy, Geoffrey L.
Foran, James M.
Traer, Elie
Stuart, Robert K.
Arellano, Martha L.
Slack, James L.
Sekeres, Mikkael A.
Willekens, Christophe
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Yang, Hua
Dai, David
Fan, Bin
Goldwasser, Meredith
Liu, Hua
Agresta, Sam
Wu, Bin
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S204 - S205
[22] Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.
Dai, David
Dinardo, Courtney Denton
Stein, Eytan
de Botton, Stephane
Attar, Eyal C.
Liu, Hua
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[23] Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.
Fan, Bin
Goyal, Lipika
Lowery, Maeve Aine
Pandya, Shuchi Sumant
Manyak, Erika
Le, Kha
Jiang, Liewen
Auer, Julia
Dai, David
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[24] Ivosidenib (IVO; AG-120) in IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Updated Results from a Phase 1 Study
DiNardo, Courtney D.
Foran, James M.
Watts, Justin M.
Stein, Eytan M.
De Botton, Stephane
Fathi, Amir T.
Prince, Gabrielle T.
Stein, Anthony S.
Stone, Richard M.
Patel, Prapti A.
Tallman, Martin S.
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Dai, David
Fan, Bin
Yen, Katherine E.
Kapsalis, Stephanie K.
Hickman, Denice
Agresta, Samuel V.
Liu, Hua
Wu, Bin
Attar, Eyal C.
Kantarjian, Hagop M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S340 - S340
[25] Ivosidenib in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 17 - 20
[26] The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
Natsume, Atsushi
Arakawa, Yoshiki
Narita, Yoshitaka
Sugiyama, Kazuhiko
Hata, Nobuhiro
Muragaki, Yoshihiro
Shinojima, Naoki
Kumabe, Toshihiro
Saito, Ryuta
Motomura, Kazuya
Mineharu, Yohei
Miyakita, Yasuji
Yamasaki, Fumiyuki
Matsushita, Yuko
Ichimura, Koichi
Ito, Kazumi
Tachibana, Masaya
Kakurai, Yasuyuki
Okamoto, Naoko
Asahi, Takashi
Nishijima, Soichiro
Yamaguchi, Tomoyuki
Tsubouchi, Hiroshi
Nakamura, Hideo
Nishikawa, Ryo
NEURO-ONCOLOGY, 2023, 25 (02) : 326 - 336
[27] Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
Foran, James M.
DiNardo, Courtney D.
Watts, Justin M.
Stein, Eytan M.
De Botton, Stephane
Fathi, Amir T.
Prince, Gabrielle T.
Stein, Anthony
Stone, Richard M.
Patel, Prapti A.
Tallman, Martin S.
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Fan, Bin
Yen, Katharine E.
Oluyadi, Abdulafeez
Winkler, Thomas
Hickman, Denice
Agresta, Samuel V.
Liu, Hua
Wu, Bin
Attar, Eyal C.
Kantarjian, Hagop M.
BLOOD, 2019, 134
[28] AG-221, AN ORAL, SELECTIVE, FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH2 MUTANT ENZYME, INDUCED DURABLE RESPONSES IN A PHASE 1 STUDY OF IDH2 MUTATION-POSITIVE ADVANCED HEMATOLOGIC MALIGNANCIES
DiNardo, C.
Stein, E. M.
Altman, J. K.
Collins, R.
DeAngelo, D. J.
Fathi, A. T.
Flinn, I.
Frankel, A.
Levine, R. L.
Medeiros, B. C.
Patel, M.
Pollyea, D. A.
Roboz, G. J.
Stone, R. M.
Swords, R. T.
Tallman, M. S.
Almon, C.
Fan, B.
Goldwasser, M.
Yen, K.
Attar, E.
de Botton, S.
HAEMATOLOGICA, 2015, 100 : 216 - 217
[29] A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)
Stein, Eytan M.
Konopleva, Marina
Gilmour, Raymond
Szpurka, Anna M.
Hill, Elizabeth
Ward, Renee
Kantarjian, Hagop M.
Dinardo, Courtney D.
BLOOD, 2020, 136
[30] Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML
Stone, Richard M.
Choe, Sung
Zhang, Vickie
Marteyn, Benoit
Penard-Lacronique, Virginie
Wang, Hongfang
DiNardo, Courtney D.
Stein, Eytan M.
Fathi, Amir T.
Tallman, Martin S.
Kantarjian, Hagop M.
Attar, Eyal C.
Wu, Bin
de Botton, Stephane
BLOOD, 2017, 130

← 1 2 3 4 5 →